Related references
Note: Only part of the references are listed.Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
Veena Shankaran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review
Taehwan Park et al.
BIODRUGS (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer
E. M. Ewara et al.
CURRENT ONCOLOGY (2014)
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer
A. Lange et al.
EUROPEAN JOURNAL OF CANCER (2014)
Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
Thomas A. Abrams et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)
Donna Lawrence et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
Arthi Vijayaraghavan et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
Ajay S. Behl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
Patricia R. Blank et al.
CLINICAL CANCER RESEARCH (2011)
Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting
Christian Asseburg et al.
CLINICAL THERAPEUTICS (2011)
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer
Thomas Winder et al.
GASTROENTEROLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
Takeru Shiroiwa et al.
MOLECULAR DIAGNOSIS & THERAPY (2010)
Assessment of K-ras Mutation A Step Toward Personalized Medicine for Patients With Colorectal Cancer
Yixing Jiang et al.
CANCER (2009)
Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
T. Maughan et al.
EJC SUPPLEMENTS (2009)
A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status
E. Van Cutsem et al.
EJC SUPPLEMENTS (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
Nicole Mittmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Herbert I. Hurwitz et al.
ONCOLOGIST (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
N. Starling et al.
BRITISH JOURNAL OF CANCER (2007)
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - A Belgian analysis
L. Annemans et al.
ACTA CLINICA BELGICA (2007)
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
J. Norum
JOURNAL OF CHEMOTHERAPY (2006)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis
P Piedbois
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
